AAAAAA

   
Results: 1-25 | 26-28
Results: 1-25/28
PROFILE OF CELL-PROLIFERATION ASSOCIATED PROTEINS IN ENDOMETRIAL CARCINOMAS (EC) INCLUDING PAP SEROUS (PAP), ENDOMETRIOID (EM) AND VILLOGLANDULAR (VG) SUBTYPES
Authors: HAYNERBUCHAN A KALLAKURY BVS SHEEHAN CE MALFETANO JH AMBROS RA ROSS JS
Citation: A. Haynerbuchan et al., PROFILE OF CELL-PROLIFERATION ASSOCIATED PROTEINS IN ENDOMETRIAL CARCINOMAS (EC) INCLUDING PAP SEROUS (PAP), ENDOMETRIOID (EM) AND VILLOGLANDULAR (VG) SUBTYPES, Modern pathology, 11(1), 1998, pp. 104-104
HER-2 NEU ONCOGENE AMPLIFICATION BY FLUORESCENCE IN-SITU HYBRIDIZATION (FISH) IN OVARIAN NEOPLASMS/
Authors: YANG F AMBROS RA KALLAKURY BVS SHEEHAN CE MALFETANO JH MURACA PJ ROSS JS
Citation: F. Yang et al., HER-2 NEU ONCOGENE AMPLIFICATION BY FLUORESCENCE IN-SITU HYBRIDIZATION (FISH) IN OVARIAN NEOPLASMS/, Modern pathology, 11(1), 1998, pp. 117-117
AMONAFIDE IN PATIENTS WITH LEIOMYOSARCOMA OF THE UTERUS - A PHASE-II GYNECOLOGIC-ONCOLOGY-GROUP STUDY
Authors: ASBURY R BLESSING JA BULLER R MALFETANO JH WALKER J SEVIN BU
Citation: R. Asbury et al., AMONAFIDE IN PATIENTS WITH LEIOMYOSARCOMA OF THE UTERUS - A PHASE-II GYNECOLOGIC-ONCOLOGY-GROUP STUDY, American journal of clinical oncology, 21(2), 1998, pp. 145-146
CELL PROLIFERATION-ASSOCIATED PROTEINS IN ENDOMETRIAL CARCINOMAS, INCLUDING PAPILLARY SEROUS AND ENDOMETRIOID SUBTYPES
Authors: KALLAKURY BVS AMBROS RA HAYNERBUCHAN AM SHEEHAN CE MALFETANO JH ROSS JS
Citation: Bvs. Kallakury et al., CELL PROLIFERATION-ASSOCIATED PROTEINS IN ENDOMETRIAL CARCINOMAS, INCLUDING PAPILLARY SEROUS AND ENDOMETRIOID SUBTYPES, International journal of gynecological pathology, 17(4), 1998, pp. 320-326
IDENTIFICATION OF HER-2 NEU ONCOGENE AMPLIFICATION BY FLUORESCENCE IN-SITU HYBRIDIZATION IN STAGE-I ENDOMETRIAL CARCINOMA/
Authors: RIBEN MW MALFETANO JH NAZEER T MURACA PJ AMBROS RA ROSS JS
Citation: Mw. Riben et al., IDENTIFICATION OF HER-2 NEU ONCOGENE AMPLIFICATION BY FLUORESCENCE IN-SITU HYBRIDIZATION IN STAGE-I ENDOMETRIAL CARCINOMA/, Modern pathology, 10(8), 1997, pp. 823-831
NONNEOPLASTIC EPITHELIAL ALTERATIONS OF THE VULVA - RECOGNITION ASSESSMENT AND COMPARISONS OF TERMINOLOGIES USED AMONG THE VARIOUS SPECIALTIES
Authors: AMBROS RA MALFETANO JH CARLSON JA MIHM MC
Citation: Ra. Ambros et al., NONNEOPLASTIC EPITHELIAL ALTERATIONS OF THE VULVA - RECOGNITION ASSESSMENT AND COMPARISONS OF TERMINOLOGIES USED AMONG THE VARIOUS SPECIALTIES, Modern pathology, 10(5), 1997, pp. 401-408
A PHASE-II TRIAL OF EDATREXATE IN PREVIOUSLY TREATED SQUAMOUS-CELL CERVICAL-CANCER - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
Authors: BROUN ER ISEMINGER KA ROSE PG LENTZ SL MALFETANO JH LINCOLN S MANNEL R
Citation: Er. Broun et al., A PHASE-II TRIAL OF EDATREXATE IN PREVIOUSLY TREATED SQUAMOUS-CELL CERVICAL-CANCER - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY, American journal of clinical oncology, 20(1), 1997, pp. 78-80
EXTENDED FIELD RADIATION AND CISPLATIN FOR STAGE IIB AND IIIB CERVICAL-CARCINOMA
Authors: MALFETANO JH KEYS H CUNNINGHAM MJ GIBBONS S AMBROS R
Citation: Jh. Malfetano et al., EXTENDED FIELD RADIATION AND CISPLATIN FOR STAGE IIB AND IIIB CERVICAL-CARCINOMA, Gynecologic oncology, 67(2), 1997, pp. 203-207
PRIMARY RADIATION, CISPLATIN, AND 5-FLUOROURACIL FOR ADVANCED SQUAMOUS CARCINOMA OF THE VULVA
Authors: CUNNINGHAM MJ GOYER RP GIBBONS SK KREDENTSER DC MALFETANO JH KEYS H
Citation: Mj. Cunningham et al., PRIMARY RADIATION, CISPLATIN, AND 5-FLUOROURACIL FOR ADVANCED SQUAMOUS CARCINOMA OF THE VULVA, Gynecologic oncology, 66(2), 1997, pp. 258-261
TELOMERASE ACTIVITY IN BENIGN ENDOMETRIUM (BE) AND ENDOMETRIAL CARCINOMA (EC)
Authors: BRIEN TP KALLAKURY BVS LOWRY CV AMBROS RA MALFETANO JH ROSS JS
Citation: Tp. Brien et al., TELOMERASE ACTIVITY IN BENIGN ENDOMETRIUM (BE) AND ENDOMETRIAL CARCINOMA (EC), Laboratory investigation, 76(1), 1997, pp. 561-561
DETERMINATION OF HER-2 NEU AMPLIFICATION (AMP) BY FLUORESCENCE IN-SITU HYBRIDIZATION (FISH) IN ENDOMETRIAL CARCINOMA (EC) - PROGNOSTIC VALUE COMPARED TO OTHER PATHOLOGICAL FEATURES/
Authors: RIBEN MW SHEEHAN CE MALFETANO JH NAZEER T AMBROS RA ROOS JS
Citation: Mw. Riben et al., DETERMINATION OF HER-2 NEU AMPLIFICATION (AMP) BY FLUORESCENCE IN-SITU HYBRIDIZATION (FISH) IN ENDOMETRIAL CARCINOMA (EC) - PROGNOSTIC VALUE COMPARED TO OTHER PATHOLOGICAL FEATURES/, Laboratory investigation, 76(1), 1997, pp. 626-626
TELOMERASE ACTIVITY IN BENIGN ENDOMETRIUM AND ENDOMETRIAL CARCINOMA
Authors: BRIEN TP KALLAKURY BVS LOWRY CV AMBROS RA MURACA PJ MALFETANO JH ROSS JS
Citation: Tp. Brien et al., TELOMERASE ACTIVITY IN BENIGN ENDOMETRIUM AND ENDOMETRIAL CARCINOMA, Cancer research, 57(13), 1997, pp. 2760-2764
HER-2 NEU ONCOGENE AMPLIFICATION BY FLUORESCENCE IN-SITU HYBRIDIZATION (FISH) IN OVARIAN NEOPLASMS/
Authors: ROSS JS YANG F AMBROS RA KALLAKURY BVS SHEEHAN CE MALFETANO JH MURACA PJ
Citation: Js. Ross et al., HER-2 NEU ONCOGENE AMPLIFICATION BY FLUORESCENCE IN-SITU HYBRIDIZATION (FISH) IN OVARIAN NEOPLASMS/, American journal of human genetics, 61(4), 1997, pp. 2131-2131
A PHASE-II TRIAL OF DIDEMNIN-B (NSC-NUMBER-335319) IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE CERVIX A GYNECOLOGIC-ONCOLOGY-GROUP STUDY - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
Authors: MALFETANO JH BLESSING JA HOMESLEY HD LOOK KY MCGEHEE R
Citation: Jh. Malfetano et al., A PHASE-II TRIAL OF DIDEMNIN-B (NSC-NUMBER-335319) IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE CERVIX A GYNECOLOGIC-ONCOLOGY-GROUP STUDY - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY, American journal of clinical oncology, 19(2), 1996, pp. 184-186
CYTOKINE, CELL-ADHESION RECEPTOR, AND TUMOR-SUPPRESSOR GENE-EXPRESSION IN VULVAR SQUAMOUS CARCINOMA - CORRELATION WITH PROMINENT FIBROMYXOID STROMAL RESPONSE
Authors: AMBROS RA KALLAKURY BVS MALFETANO JH MIHM MC
Citation: Ra. Ambros et al., CYTOKINE, CELL-ADHESION RECEPTOR, AND TUMOR-SUPPRESSOR GENE-EXPRESSION IN VULVAR SQUAMOUS CARCINOMA - CORRELATION WITH PROMINENT FIBROMYXOID STROMAL RESPONSE, International journal of gynecological pathology, 15(4), 1996, pp. 320-325
CLINICOPATHOLOGICAL FEATURES OF VULVAR SQUAMOUS-CELL CARCINOMAS EXHIBITING PROMINENT FIBROMYXOID STROMAL RESPONSE
Authors: AMBROS RA MALFETANO JH MIHM MC
Citation: Ra. Ambros et al., CLINICOPATHOLOGICAL FEATURES OF VULVAR SQUAMOUS-CELL CARCINOMAS EXHIBITING PROMINENT FIBROMYXOID STROMAL RESPONSE, International journal of gynecological pathology, 15(2), 1996, pp. 137-145
IFOSFAMIDE AND DOXORUBICIN IN THE TREATMENT OF ADVANCED LEIOMYOSARCOMAS OF THE UTERUS - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
Authors: SUTTON G BLESSING JA MALFETANO JH
Citation: G. Sutton et al., IFOSFAMIDE AND DOXORUBICIN IN THE TREATMENT OF ADVANCED LEIOMYOSARCOMAS OF THE UTERUS - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY, Gynecologic oncology, 62(2), 1996, pp. 226-229
PERIPHERAL INFUSION PORTS FOR CENTRAL VENOUS ACCESS IN PATIENTS WITH GYNECOLOGIC MALIGNANCIES
Authors: CUNNINGHAM MJ COLLINS MB KREDENTSER DC MALFETANO JH
Citation: Mj. Cunningham et al., PERIPHERAL INFUSION PORTS FOR CENTRAL VENOUS ACCESS IN PATIENTS WITH GYNECOLOGIC MALIGNANCIES, Gynecologic oncology, 60(3), 1996, pp. 397-399
A PHASE-II TRIAL OF GALLIUM NITRATE (NSC NUMBER-15200) IN NONSQUAMOUSCELL-CARCINOMA OF THE CERVIX - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
Authors: MALFETANO JH BLESSING JA HOMESLEY HD
Citation: Jh. Malfetano et al., A PHASE-II TRIAL OF GALLIUM NITRATE (NSC NUMBER-15200) IN NONSQUAMOUSCELL-CARCINOMA OF THE CERVIX - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY, American journal of clinical oncology, 18(6), 1995, pp. 495-497
PERCUTANEOUS GASTROSTOMY FOR DECOMPRESSION IN PATIENTS WITH ADVANCED GYNECOLOGIC MALIGNANCIES
Authors: CUNNINGHAM MJ BROMBERG C KREDENTSER DC COLLINS MB MALFETANO JH
Citation: Mj. Cunningham et al., PERCUTANEOUS GASTROSTOMY FOR DECOMPRESSION IN PATIENTS WITH ADVANCED GYNECOLOGIC MALIGNANCIES, Gynecologic oncology, 59(2), 1995, pp. 273-276
P53 GENE STATUS IN ENDOMETRIAL CARCINOMAS SHOWING DIFFUSE POSITIVITY FOR P53 PROTEIN BY IMMUNOHISTOCHEMISTRY (IMH)
Authors: KALLAKURY BVS AMBROS RA ROSS JS MALFETANO JH KIM Y HWANG J FIGGE J
Citation: Bvs. Kallakury et al., P53 GENE STATUS IN ENDOMETRIAL CARCINOMAS SHOWING DIFFUSE POSITIVITY FOR P53 PROTEIN BY IMMUNOHISTOCHEMISTRY (IMH), Laboratory investigation, 72(1), 1995, pp. 91-91
MULTIVARIATE SURVIVAL ANALYSIS OF CLINICOPATHOLOGICAL FEATURES IN SURGICAL STAGE-I ENDOMETRIOID CARCINOMA INCLUDING ANALYSIS OF HER-2 NEU EXPRESSION/
Authors: NAZEER T BALLOUK F MALFETANO JH FIGGE H AMBROS RA
Citation: T. Nazeer et al., MULTIVARIATE SURVIVAL ANALYSIS OF CLINICOPATHOLOGICAL FEATURES IN SURGICAL STAGE-I ENDOMETRIOID CARCINOMA INCLUDING ANALYSIS OF HER-2 NEU EXPRESSION/, American journal of obstetrics and gynecology, 173(6), 1995, pp. 1829-1834
METHODS IN PATHOLOGY - COMPARATIVE QUANTITATIVE IMMUNOHISTOCHEMICAL AND IMMUNORADIOMETRIC DETERMINATIONS OF CATHEPSIN-D IN ENDOMETRIAL ADENOCARCINOMA - PREDICTORS OF TUMOR AGGRESSIVENESS
Authors: NAZEER T CHURCH K AMATO C AMBROS RA ROSANO TG MALFETANO JH ROSS JS
Citation: T. Nazeer et al., METHODS IN PATHOLOGY - COMPARATIVE QUANTITATIVE IMMUNOHISTOCHEMICAL AND IMMUNORADIOMETRIC DETERMINATIONS OF CATHEPSIN-D IN ENDOMETRIAL ADENOCARCINOMA - PREDICTORS OF TUMOR AGGRESSIVENESS, Modern pathology, 7(4), 1994, pp. 469-474
SIGNIFICANCE OF PAPILLARY (VILLOGLANDULAR) DIFFERENTIATION IN ENDOMETRIOID CARCINOMA OF THE UTERUS
Authors: AMBROS RA BALLOUK F MALFETANO JH ROSS JS
Citation: Ra. Ambros et al., SIGNIFICANCE OF PAPILLARY (VILLOGLANDULAR) DIFFERENTIATION IN ENDOMETRIOID CARCINOMA OF THE UTERUS, The American journal of surgical pathology, 18(6), 1994, pp. 569-575
A PHASE-II TRIAL OF IFOSFAMIDE AND MESNA IN PATIENTS WITH ADVANCED ORRECURRENT MIXED MESODERMAL TUMORS OF THE OVARY PREVIOUSLY TREATED WITH PLATINUM-BASED CHEMOTHERAPY - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
Authors: SUTTON GP BLESSING JA HOMESLEY HD MALFETANO JH
Citation: Gp. Sutton et al., A PHASE-II TRIAL OF IFOSFAMIDE AND MESNA IN PATIENTS WITH ADVANCED ORRECURRENT MIXED MESODERMAL TUMORS OF THE OVARY PREVIOUSLY TREATED WITH PLATINUM-BASED CHEMOTHERAPY - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY, Gynecologic oncology, 53(1), 1994, pp. 24-26
Risultati: 1-25 | 26-28